ArticleStudies in health technology and informatics2022
Associations Between Aggregate NLP-Extracted Conflicts of Interest and Adverse Events by Drug Product.
Article in Studies in health technology and informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Research on policy mechanisms to address funding bias and conflicts of interest in biomedical research: a scoping review.Research integrity and peer review · 2025Article
- Beyond Bias: Aggregate Approaches to Conflicts of Interest Research and Policy in Biomedical Research.World medical & health policy · 2024Article
- Sample Size Considerations for Fine-Tuning Large Language Models for Named Entity Recognition Tasks: Methodological Study.JMIR AI · 2024Article
- Undisclosed financial conflicts of interest in DSM-5-TR: cross sectional analysis.BMJ (Clinical research ed.) · 2024Article
- Article
- Evidence for stratified conflicts of interest policies in research contexts: a methodological review.BMJ open · 2022Review
- A Content Analysis of Self-Reported Financial Relationships in Biomedical Research.AJOB empirical bioethicsArticle
- Psychedelics in PERIL: The Commercial Determinants of Health, Financial Entanglements and Population Health Ethics.Public health ethicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
This study evaluates associations between aggregate conflicts of interest (COI) and drug safety. We used a machine-learning system to extract and classify COI from PubMed-indexed disclosure statements. Individual conflicts were classified as Type 1 (personal fees, travel, board memberships, and non-financial support), Type 2 (grants and research support), or Type 3 (stock ownership and industry employment). COI were aggregated by type compared to adverse events by product. Type 1 COI are associated with a 1.1-1.8% increase in the number of adverse events, serious events, hospitalizations, and deaths. Type 2 COI are associated with a 1.7-2% decrease in adverse events across severity levels. Type 3 COI are associated with an approximately 1% increase in adverse events, serious events, and hospitalizations, but have no significant association with adverse events resulting in death. The findings suggest that COI policies might be adapted to account the relative risks of different types of financial relationships.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.